Compare
Gilead Sciences vs Bristol-Myers Squibb
MonkScore ranges and fundamentals, side by side
Key facts
Gilead Sciences and Bristol-Myers Squibb: key facts
- In fiscal 2025, Gilead Sciences, Inc. reported revenue of $29.4B and net income of $8.5B.
- In fiscal 2025, Bristol-Myers Squibb Company reported revenue of $48.2B and net income of $7.1B.
- Gilead Sciences, Inc.'s revenue grew 1.9% a year from fiscal 2021 to fiscal 2025.
- Bristol-Myers Squibb Company's revenue grew 1.0% a year from fiscal 2021 to fiscal 2025.
- Gilead Sciences, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- Bristol-Myers Squibb Company's free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Gilead Sciences, Inc. reported revenue of $31.0B and net income of -$3.9B.
- In the twelve months to 30 September 2026, Bristol-Myers Squibb Company reported revenue of $50.0B and net income of $9.2B.
Side by side
Gilead Sciences and Bristol-Myers Squibb, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Gilead Sciences, Inc.NASDAQ:GILD | Bristol-Myers Squibb CompanyNYSE:BMY |
|---|---|---|
| MonkScore | ||
| MonkScore range | 90–100as of October 2026 | 80–90as of October 2026 |
| Sector rank | 39 of 628 in Healthcare | 137 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Latest fiscal year | ||
| Revenue | $29.4BFY 2025 | $48.2BFY 2025 |
| Net income | $8.5BFY 2025 | $7.1BFY 2025 |
| Free cash flow | $9.5BFY 2025 | $12.8BFY 2025 |
| Operating cash flow | $10.0BFY 2025 | $14.2BFY 2025 |
| Total debt | $24.9BFY 2025 | $47.1BFY 2025 |
| Cash | $7.6BFY 2025 | $10.2BFY 2025 |
| Last 12 months | ||
| Revenue | $31.0Bto 30 September 2026 | $50.0Bto 30 September 2026 |
| Net income | -$3.9Bto 30 September 2026 | $9.2Bto 30 September 2026 |
| Free cash flow | $14.0Bto 30 September 2026 | $9.3Bto 30 September 2026 |
| Operating cash flow | $14.5Bto 30 September 2026 | $10.7Bto 30 September 2026 |
| Total debt | $26.2Bto 30 September 2026 | $42.9Bto 30 September 2026 |
| Cash | $6.4Bto 30 September 2026 | $9.6Bto 30 September 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.